In news dated October 29, 2025, Lantheus, headquartered in North Billerica, Massachusetts, announced on Tuesday that the U.S. FDA has accepted its application for a novel Alzheimer's disease PET imaging agent. This development brings new hope for Alzheimer's disease diagnosis, and related diagnostic methods and imaging agents have started receiving increased attention.

Prior to this, Lantheus announced positive results from two "critical" studies. The company is advancing the commercialization process of MK-6240, a radiodiagnostic agent targeting tau protein tangles. Tau protein tangles are a key marker of various neurodegenerative diseases, and MK-6240 successfully met its primary endpoints related to sensitivity and specificity, with experimental data strongly supporting the New Drug Application. If everything progresses as planned, the FDA is expected to make a decision by August 2026.

Lantheus CEO Brian Markison stated in a press release on October 28: "We are pleased that the FDA has accepted our Fast Track application for MK-6240, which highlights the urgent need for innovative Alzheimer's disease diagnostic tools and MK-6240's potential to meet this need..." He further added, "If approved, MK-6240 will complement beta-amyloid PET imaging and emerging blood diagnostic technologies, helping to guide treatment strategies for healthcare professionals and patients."

Markison also noted that currently over 100 Alzheimer's disease modifying therapies are in development. Approximately 30 of these target tau protein pathology, with MK-6240 being one of them; another 40 are related to beta-amyloid protein. Currently, about 12 million people suffer from mild cognitive impairment, and the prevalence rate will continue to rise with population aging. Lantheus stated that given this growth trend, the Alzheimer's radiodiagnostic market in the United States is expected to reach 400,000 scans by 2030, with a market size of $ 1.5 billion.

MK-6240 is designed to target aggregated tau protein in the form of neurofibrillary tangles, which is a hallmark of various neurodegenerative diseases. Key clinical studies have shown that the drug has high affinity for tau protein with limited off-target binding. Lantheus acquired this drug in 2023, which had previously received Fast Track designation and is currently being studied in nearly 100 active clinical trials. In its announcement, Lantheus stated, "We expect MK-6240 will help enable earlier disease detection, patient staging, treatment selection and monitoring, and may potentially help establish tau as a surrogate endpoint for treatment efficacy."

Source: China Nuclear Technology Network